STOCK TITAN

NewGenIVF pays $4.71M in Ras Al Khaimah land deposits

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

NewGenIVF Group Ltd (NIVF) updated on its medical-device, K25.ai, real-estate and IVF businesses. It completed an acquisition of 2% of PredicXion Group Limited, which operates K25.ai, and agreed to acquire a further 11%. K25 Group announced on November 10, 2026 that it plans to launch K25.fun this month for K-pop audiences in Asia-Pacific.

NewGen engaged Shenzhen Siyu as a consultant for registration of its NX One platform with China’s National Medical Products Administration. Wholly owned subsidiary Nodexus signed a non-binding collaboration agreement with Hainan Provincial Cancer Hospital on validation and clinical research; the agreement records the parties’ intent, and there can be no assurance a definitive agreement will be entered into. NewGen paid US$4.71 million in deposits toward land for its Ras Al Khaimah project, but has not executed a definitive sale and purchase agreement. IVF revenue was broadly flat for the six months ended June 30, 2026, versus the same 2025 period; management cited lower industry demand and the Thailand-Cambodia conflict’s effect on patient travel.

At June 30, 2026, unaudited cash was approximately US$1.02 million and total assets approximately US$36.4 million, including the land deposit. Equity attributable to company shareholders was approximately US$26.4 million; total shareholders’ equity, including non-controlling interests, was approximately US$25.7 million.

Filing Explained

The update adds unresolved project-funding and deposit-recovery risks, alongside a possible—not completed—dilution path through a Nodexus listing.

In this business update, NewGen flags a risk that it may not fund the remaining cash consideration for its agreed further K25 investment, and that its land deposit may not be recovered.

The release describes a Nodexus listing as potential and says it could dilute NewGen’s interest; that is a possible future ownership change, not a reported completed dilution.

Completed K25.ai-related equity acquisition 2% Equity interest in PredicXion Group Limited, which operates K25.ai
Further K25.ai-related equity acquisition agreed 11% Further equity interest in PredicXion Group Limited
Land acquisition deposits US$4.71 million Deposits paid toward land for the Ras Al Khaimah real-estate project
Cash and cash equivalents Approximately US$1.02 million As of June 30, 2026; unaudited
Total assets Approximately US$36.4 million As of June 30, 2026; includes US$4.71 million in land acquisition deposits
Equity attributable to company shareholders Approximately US$26.4 million As of June 30, 2026; unaudited
Total shareholders’ equity Approximately US$25.7 million As of June 30, 2026; includes non-controlling interests
microfluidic platform technical
"registration of its NX One microfluidic platform"
National Medical Products Administration regulatory
"registration with China’s National Medical Products Administration"
The National Medical Products Administration is the government agency responsible for reviewing, approving and supervising drugs, vaccines, medical devices and related products. Think of it as the country’s gatekeeper for medical products: its decisions determine whether a product can be sold, how quickly it reaches patients and what safety or labeling requirements apply, so its rulings directly affect a company’s sales prospects, regulatory risk and investor valuation.
real-world data medical
"collaboration to generate real-world data"
Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.
non-controlling interests financial
"total shareholders’ equity, including non-controlling interests"
An ownership stake in a subsidiary held by outside shareholders rather than the parent company, representing the portion of that subsidiary’s assets and profits the parent does not control. For investors, it shows what part of consolidated earnings and equity belongs to others — like a roommate who owns part of a house — which affects how much value and profit per share are truly attributable to the parent company’s shareholders.
prediction-market technical
"regulatory risk specific to prediction-market and information-market products"
A prediction market is a trading platform where people buy and sell small claims tied to the outcome of a future event, and the market price acts like a collective probability or “odds” for that outcome. For investors, these markets offer a real-time, crowd-sourced signal about likely future events—similar to polling or betting odds—which can help gauge risk, sentiment and possible impacts on asset values.
assisted reproductive treatment medical
"IVF and assisted reproductive treatment business"
Assisted reproductive treatment is a set of medical procedures and lab techniques that help people achieve pregnancy when natural conception is difficult, including in vitro fertilization, intrauterine insemination, and use of donor gametes or surrogacy. Think of it like using specialized tools and a controlled lab process to help a seed take root. It matters to investors because demand, reimbursement, regulation and technology advances directly affect revenues for clinics, device makers and related service providers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much of K25.ai has NIVF acquired?

NewGen completed the acquisition of 2% of PredicXion Group Limited, which operates K25.ai, and agreed to acquire a further 11% of its equity interests.

How much has NIVF paid toward the Ras Al Khaimah land?

NewGen paid US$4.71 million in deposits toward the land acquisition. A definitive sale and purchase agreement for the land has not yet been executed.

How did NIVF’s IVF revenue change in the first half of 2026?

Revenue from NewGen’s IVF and assisted reproductive treatment business was broadly flat for the six months ended June 30, 2026, compared with the same period in 2025. Management attributed this to lower industry demand and the Thailand-Cambodia conflict’s effect on patient travel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-42004

 

NEWGENIVF GROUP LIMITED

(Exact name of registrant as specified in its charter)

 

36/39-36/40, 13th Floor, PS Tower

Sukhumvit 21 Road (Asoke)

Khlong Toei Nuea Sub-district

Watthana District, Bangkok 10110

Thailand

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒                   Form 40-F ☐

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 16, 2026

 

  NEWGENIVF GROUP LIMITED
     
  By: /s/ Wing Fung Alfred Siu
  Name: Wing Fung Alfred Siu
  Title: Chairman of the Board and Director

 

2

Exhibit 99.1

 

NewGen Provides Business Update

 

BANGKOK, November 16, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today provided an update on its businesses.

 

Nodexus and NX One

 

In July 2025, the Company acquired advanced cytometry intellectual property and equipment. The Company has engaged Shenzhen Siyu Enterprise Management Consulting Co., Ltd. as its regulatory consultant for registration of its NX One microfluidic platform with China’s National Medical Products Administration (“NMPA”).

 

Nodexus Limited, a wholly owned Hong Kong subsidiary of the Company, has also signed a non-binding collaboration agreement with Hainan Provincial Cancer Hospital. The agreement records the parties’ intent to collaborate on scientific validation, clinical research and eventual clinical translation of the NX One device in tumor precision diagnosis and treatment and in cell research. The parties intend the collaboration to generate real-world data that may support future clinical validation and clinical application of NX One in China. The agreement is non-binding, and there can be no assurance that a definitive agreement will be entered into.

 

K25.ai

 

The Company has completed the acquisition of 2% of the equity interest in PredicXion Group Limited, which operates K25.ai. The Company has also agreed to acquire a further 11% of equity interests. On November 10, 2026, K25 Group announced that it plans to launch K25.fun this month. K25.fun is a new membership platform bringing exclusive concert experiences, limited-edition collectibles, and fan quests to K-pop audiences across Asia-Pacific. This launch demonstrates K25’s ability to turn audience engagement into new consumer revenue verticals.

 

Ras Al Khaimah Real Estate Project

 

The Company has paid deposits of US$4.71 million toward the acquisition of land for its real estate development project in Ras Al Khaimah, United Arab Emirates. A definitive sale and purchase agreement for the land has not yet been executed.

 

IVF Business

 

Revenue from the Company’s IVF and assisted reproductive treatment business was broadly flat for the six months ended June 30, 2026 compared with the same period in 2025. Management attributes this to lower demand for fertility services across the industry and the effect of the Thailand–Cambodia conflict on patient travel.

 

 

 

 

Selected Balance Sheet Data (unaudited)

 

As of June 30, 2026, as reflected in the Company’s unaudited condensed consolidated financial statements for the six months then ended furnished on Form 6-K/A on October 27, 2026:

 

Cash and cash equivalents were approximately US$1.02 million.

 

Total assets were approximately US$36.4 million, including deposits for land acquisition of US$4.71 million.

 

Equity attributable to shareholders of the Company was approximately US$26.4 million.

 

Total shareholders’ equity, including non-controlling interests, was approximately US$25.7 million.

 

The increase in total assets compared with June 30, 2025 primarily reflects the acquisition of the cytometry intellectual property in July 2025 and the Company’s investment in K25.ai.

 

About NewGen

 

NewGenIVF Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.

 

About Shenzhen Siyu Enterprise Management Consulting Co., Ltd.

 

Shenzhen Siyu (www.siyu-com.com) is a regulatory consulting firm experienced in China medical device registration. It is serving as full-process regulatory consultant to NewGen for the NX One NMPA registration program, including classification strategy, type-testing coordination, dossier preparation, and regulatory communications.

 

About Nodexus Limited

 

Nodexus Limited is a Hong Kong-incorporated company and the developer of the NX One microfluidic platform. It is a subsidiary within the NewGen group focused on advancing the commercialization of NX One for precision oncology applications.

 

2

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company’s plans to seek registration of NX One with the NMPA and the U.S. Food and Drug Administration; the potential listing of Nodexus Limited under Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; the proposed collaboration with Hainan Provincial Cancer Hospital; the completion of the Company’s investment in K25.ai, including payment of the remaining cash consideration; the planned launch of K25.fun; the completion of the land acquisition for the Company’s real estate development project in Ras Al Khaimah; and trends in the Company’s IVF and assisted reproductive treatment business.

  

These forward-looking statements are based on the Company’s current expectations, estimates, projections and assumptions as of the date of this press release and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. These risks and uncertainties include, among others: the risk that required regulatory registrations for NX One are not obtained or are subject to material delay; the risk that the collaboration with Hainan Provincial Cancer Hospital does not proceed or does not generate supportive data; the risk that the potential listing of Nodexus Limited does not occur, and that any such listing dilutes the Company’s interest in Nodexus Limited; the possibility that the K25.ai transaction is not completed on the terms described or at all, including the Company’s ability to fund its remaining payment obligations; the risk that the carrying value of the Company’s investment in K25.ai is not realized and may be impaired; risks generally associated with strategic investments, including the Company’s limited control over K25.ai’s business; regulatory risk specific to prediction-market and information-market products; the risk that no definitive agreement for the Ras Al Khaimah land is concluded or that the Company’s deposits are not recovered; geopolitical risks, including conflict in the Middle East and between Thailand and Cambodia; changes in demand for fertility services; liquidity and capital requirements risk; and business transformation and execution risk arising from the Company’s ongoing strategic pivot across multiple new business lines. Additional risks are described in the Company’s Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.

 

All information provided in this press release is as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable securities laws.

 

Contacts

 

ICR, LLC

 

Robin Yang

 

Phone: +1 (212) 537-3847

 

Email: Newgenivf.IR@icrinc.com

 

3

 

 

 

Filing Exhibits & Attachments

1 document

Keep reading